Examining Hepatitis C Reinfection Rates in Kenya

Yale University

Status: Completed

Conditions: Hepatitis C

Study type: Observational

Funder types: Other

Identifiers

NCT03564639

1512016965_B

Details and patient eligibility

About

The goal of this research project is to build upon the Testing and Linkage to Care for Injecting Drug Users (TLC-IDU) parent study and describe post-cure HCV reinfection in a population of people who inject drugs (PWIDs) in Kenya.

Full description

In addition to describing reinfection in a substance using cohort, we will identify individual predictors of HCV reinfection in Kenya, as well as identifying individual utilization intervention approaches and dosing that reduce reinfection risk and treatment cite level risk factors (frequency of visits, community vs hospital location etc.). Determining the risk factors specific to reinfection and understanding the impact of concurrent harm reduction interventions will guide service delivery and implementation of HCV elimination strategies in Kenya and throughout the region.

Enrollment: 101 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Live in Nairobi or coastal Mombasa (Coast Province including Malindi), Kenya;
2. Are injection drug users (IDUs) that ever injected any non-prescribed drugs; and able and willing to provide informed consent.
3. Participates are in the parent study;
4. Complete treatment protocol; and achieve a sustained virologic response (SVR).

Exclusion criteria

Not in the above inclusion criteria.

Trial design

101 participants in 1 patient group

Injection drug users with HCV

Description:

People who inject drugs who were confirmed positive for HCV and initiated treatment in the parent study beginning in September 2017.